CAMBRIDGE, Mass., October 2, 2023 – Sumitomo Pharma America, Inc. (SMPA) today announced Ron Gimbel has been appointed as the Company’s new Chief Financial Officer. Mr. Gimbel, an industry veteran with more than 25 years of experience building and leading robust finance and operations teams in the biopharmaceutical sector, joins SMPA from Flagship Pioneering, where he served as Chief Financial Officer of Flagship Labs and Enterprise since 2021.
As CFO of SMPA, Mr. Gimbel will be responsible for the financial management of the Company, including leading all finance functions, business planning and analysis, investor relations, and global business services.
“The leadership team and I are thrilled to welcome Ron to Sumitomo Pharma America, as he will be instrumental in fueling future potential investments and driving business growth,” said Myrtle Potter, President and Chief Executive Officer of SMPA. “Ron is a proven and well-respected leader with an impressive record in building and leading financial global operations. We are confident his extensive expertise in finance, manufacturing operations and global markets will be an ideal fit for our next chapter at Sumitomo Pharma America.”
“I am honored to take on this new role at SMPA during this pivotal growth period for the company and continue the positive momentum the business has achieved,” said Ron Gimbel, Chief Financial Officer of SMPA. “I look forward to working with Myrtle and the rest of the leadership team to execute a substantial long-term growth strategy and deliver on the Company’s unwavering commitment to the development of innovative treatments to address areas of unmet need.”
Prior to joining Flagship Pioneering, Mr. Gimbel served in various leadership positions at Bristol-Myers Squibb Company contributing to its evolution from a large-cap pharmaceutical company to a next-generation biopharma company. During his 20-plus years at Bristol-Myer Squibb, Mr. Gimbel was responsible for building and leading robust financial operations globally and achieved steady career progression in manager, director, executive director and vice president level roles including, managing director of finance, BMS Japan, assistant treasurer, head of finance for global manufacturing and product supply, chief audit officer (CAO) and head of global research & development. He received his BS in Finance and MBA from Colorado State University.
Mr. Gimbel will assume the Chief Financial Officer role effective immediately.
About Sumitomo Pharma Group
Sumitomo Pharma Group is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.) and Europe (Sumitomo Pharma Switzerland GmbH) focused on addressing unmet patient needs in psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies. With several marketed products in the U.S., Europe, and Canada, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, Sumitomo Pharma America and Switzerland aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. Sumitomo Pharma America and Switzerland are companies of Sumitomo Pharma Co., Ltd. For more information, please visit https://www.us.sumitomo-pharma.com and LinkedIn to follow us.
The Sumitomo Pharma icon is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license.
Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd.
© 2023 Sumitomo Pharma America, Inc. All rights reserved.
For a copy of this release, visit Sumitomo Pharma America’s website at www.us.sumitomo-pharma.com.